



РЕПУБЛИКА БЪЛГАРИЯ

Министерство на здравеопазването

Министър на здравеопазването

ЗАПОВЕД

24.6.2024 г.

X РД-01-387/24.06.2024 г.

Signed by: IVO TSVETANOV MANCHEV

На основание чл. 25, ал. 4 от Закона за администрацията, чл. 266а, ал. 2 от Закона за лекарствените продукти в хуманната медицина, чл. 16, ал. 4 от Наредба № 10 от 2011 г. за условията и реда за лечение с неразрешени за употреба в Република България лекарствени продукти, лекарствени продукти, прилагани извън условията на разрешението за употреба и лекарствени продукти за състрадателна употреба, както и за условията и реда за включване, промени, изключване и доставка на лекарствени продукти от списъка по чл. 266а, ал. 2 от Закона за лекарствените продукти в хуманната медицина

НАРЕЖДАМ:

I. Утвърждавам списък на лекарствените продукти по чл. 266а, ал. 2 от Закона за лекарствените продукти в хуманната медицина, съгласно Приложението.

II. Отменям Заповед № РД-01-356/22.06.2023 г. за утвърждаване на списък на лекарствените продукти по чл. 266а, ал. 2 от Закона за лекарствените продукти в хуманната медицина, допълнена със Заповед № РД-01-377/10.07.2023 г., Заповед № РД-01-403/21.07.2023 г. Заповед № РД-01- 412/27.07.2023 г., Заповед № РД-01-470/22.08.2023 г., Заповед № РД-01-536/03.10.2023 г., Заповед № РД-01-623/14.11.2023 г., Заповед № РД-01-623/14.11.2023 г., Заповед № РД-01-704/21.12.2023 г., Заповед РД-01-708/22.12.2023 г., Заповед РД-01-16/16.01.2024 г., Заповед РД-01-25/19.01.2024 г., Заповед РД-01-64/09.02.2024 г. и Заповед № РД-01-364/30.05.2024 г.

III. Настоящата заповед да се публикува на интернет страницата на Министерството на здравеопазването.

24.6.2024 г.

X Kondeva

Д-р Галя Кондева

Министър на здравеопазването

Signed by: Galya Georgieva Kondeva-Mankova

Приложение

СПИСЪК

на лекарствените продукти по чл. 266а, ал. 2 от Закона за лекарствените продукти в хуманната медицина

| № | Код по анатомо-терапевтично-химичната класификация | Международно непатентно наименование, към което принадлежи продуктът | Лекарствена форма и количество активно вещество | Заболяване по международен код на заболяванията | Допълнителна информация |
|---|--|--|--|--|-------------------------|
| 1 | C01EA01 | Alprostadil | 20 mcg powder for solution for infusion x 10 | I70.2, I73.0, I73.1, I74.2, I74.3, I74.5 | |
| 2 | L01XD04 | Aminolevulinic acid | 30 mg/ml powder for oral solution - 50 ml | C71.0 | |
| 3 | L04AC03 | Anakinra | Solution for injection 100 mg/0,67 ml in pre-filled syringe | U07.1, M08.2, M35.8, M05.8, M06.1, M08.2, M10.0, M11.8, D84.9, M35.2 | |
| 4 | L01XX27 | Arsenic trioxide | 1 mg/ml concentrate for solution for infusion - 10 ml | C92.4 | |
| 5 | P01BF05 | Arteminol and Piperaquine | 320 mg/40 mg film-coated tablets x 3; x 6; x 9; x 12; x 270; x 300 | B50 | |
| 6 | P01BE03 | Artesunate | 110 mg - Powder and solvent for solution for injection- 2 vials + 2 vials; 4 vials + 4 vials | B50 | |
| 7 | L01XX02 | Asparaginase/ L-asparaginase | 10 000 U powder for concentrate for solution for infusion x 1; x 5 | C91.0 | |
| 8 | M09AX03 | Ataluren | 1000 mg granules for oral suspension x 30 sachets | G71.0 | |

| | | | | | |
|----|---------|-------------------------------------|---|--|--|
| 9 | J01DF01 | Aztreonam | 75 mg powder and solvent for nebuliser solution - 84 vials + 88 ampoules; 84 vials + 88 ampoules + 1 altera nebuliser handset | E84.0 | |
| 10 | H01CB01 | Betaine anhydrous | 1 g oral powder | E71.2 | |
| 11 | D03AX13 | Betulae cortex (Birch bark extract) | Gel Cutaneous 9,4 g ; 23,4 g | Q81.1, Q81.2 | |
| 12 | M05BX05 | Burosumab | solution for injection 10 mg/ml; solution for injection 20 mg/ml; solution for injection 30 mg/ml; | E83.3 | |
| 13 | L01AB01 | Busulfan | 6 mg/ml concentrate for solution for infusion -10 ml x 8 (8 x 1) vials | C90, C81, C82, C83, C85, C91, C92, D46, D47;D61.0, D61, D61.0, D61.1, D61.2, D61.3 | |
| 14 | B06AC01 | C1- inhibitor, plasma derived | Powder and solvent for solution for injection 3000 IU - vial x 1; x 5; x 20; Powder and solvent for solution for injection 2000 IU- vial x 1; x 5; x 20 | D84.1 | |
| 15 | L01EX07 | Cabozantinib | film-coated tablets 60 mg x 30 film-coated tablets 20 mg x 30 | C64, C22.0, C73 | |
| 16 | L04AC08 | Canakinumab | 150 mg powder for solution for injection vial | M06.1, M10.0, D84.9 | |
| 17 | N03AX24 | Cannabidiol | 100 mg/ml oral solution (1 x 100 ml bottle+2 syringes of 1 ml + 2 syringes of 5ml+2 bottle adaptors и 3 x100 ml bottles+2 syringes of 1 ml+2 syringes of 5 ml+3 bottle adaptors.) | G40.4; G40.6 | |
| 18 | B01AX07 | Caplacizumab | 10 mg/10 ml powder and solvent for solution for injection | M31.1, D69.3 | |
| 19 | A16AA05 | Carglumic acid | dispersible tablets 200 mg x 5; 15; 12; 60 | E71.0, E71.1, E72.2 | |
| 20 | L01AD01 | Carmustin | Powder and solvent for concentrtrate for solution for infusion 100 mg | C81, C82, C83, C84, C85, C71, C15-C26, C43 | |

| | | | | | |
|----|---------|-------------------------|--|---|--|
| 21 | J06BD07 | Casirivimab/Imdevimab | 300 mg + 300 mg solution for injection/infusion - 2,5 ml (300mg of casirivimab per 2,5 ml and 300 mg of imdevimab per 2,5 ml);120mg/ml + 120mg/ml solution for injection/infusion -11,1 ml (1332mg of casirivimab per 11,1 ml and 1332 mg of imdevimab per 11,1 ml) | U07.1 | |
| 22 | J02AX04 | Caspofungin | 50 mg powder for concentrate for solution for infusion x 1 vial; 70 mg powder for concentrate for solution for infusion x 1 vial | Съгласно РУ | |
| 23 | J01DI04 | Cefiderocol | 1 g powder for concentrate for solution for infusion | B96.5, B96.1, B96.2, U83.7 | |
| 24 | B02BD07 | Coagulation factor XIII | 250 IU powder and solvent for solution for injection/infusion x 1 vial; 1250 IU powder and solvent for solution for injection/infusion x 1 vial | D68.2 | |
| 25 | L01AA01 | Cyclophosphamide | 50 mg coated tablets x 50; 200; 500; 1000 | G70.2;C82.0,C82.1,C82.2,C82.7, C82.9, C84.4, C84.5, C85.1,C85.7,C85.9, C88.0, C88.9, C90.0, C90.1, C90.2, C92.0, C92.1, C92.3, C92.7, C95.0,C95.1,C95.2,C95.7, C91.1, D59.1, D69.3, D69.0, M30.2, M31.3, M32.1, M32.8, M33.0, M33.2; C91.0, C81, C85, C90, C56, C62, C50, C34, C74, C41, C49, C41, C92; N01.0 до N01.8; N00.0 до N00; N03.0 до N03.8; N04.0 до N04.8; N05.0 до N05.9; M32.1*; N08.5; M30.0*; M31.0*; M31.1*; M31.3*; N16.4; N08.2; E85;*N08.4 | |

| | | | | | |
|----|--------------------|---|--|--|--|
| 26 | L01BC08 | Decitabine | 50 mg powder for concentrate for solution for infusion x 1 vial | C92.0 | |
| 27 | B01AX01 | Defibrotide | 80 mg/ml concentrate for solution for infusion -2.5 ml | C90, C81, C82, C83, C85, C91, C92, D46, D47, D61 | |
| 28 | N05CM18 | Dexmedetomidine | concentrate for solution for infusion 100 micrograms/ml - 2ml; 4 ml; | СЪГЛАСНО РУ | |
| 29 | L01XC16 L01FX06 | Dinutuximab beta | 4.5 mg/ml Concentrate for solution for infusion, 20 mg, 1 vial | от C76.0 до C76.5 | |
| 30 | A16AB26 | Eladocagene exuparvovec | 2.8×10^{11} vector genomes(vg)/0.5mL solution for infusion | E70.8 | |
| 31 | A12BA30 | Electrolytes - Potassium (different salts in combination) | 8 mEq prolonged-release granules; 24 mEq prolonged-release granules | N13-N15 | |
| 32 | B05XA31 | Electrolytes in combination with other drugs | Concentrate for solution for infusion -10 ml | K90.8, K90.9, K91.2, K91.8, P78.3 | Състав на 1 ampoule (10 ml): Zinc chloride - 10420 micrograms; Copper chloride dihydrate -1074 micrograms Manganese chloride tetrahydrate - 36.00 micrograms Sodium selenite 153.3 micrograms Potassium iodide 25.67 micrograms |

| | | | | | |
|----|--------------------|--|---|---|--|
| 33 | L01XC23 L01FX08 | Elotuzumab | powder for concentrate for solution for infusion 300 mg; powder for concentrate for solution for infusion 400 mg | C90.0 | |
| 34 | J05AF10 | Entecavir | 0,05 mg/ml oral solution - 210 ml | B18; K 74.6 | Entecavir като oral solution е предназначен за лечение на хронична HBV инфекция в детска възраст |
| 35 | B01AC16 | Eptifibatide | 0,75 mg/ml solution for injection - 100ml | I20, I21, I22, I23, I24, I25 | |
| 36 | L01CB01 | Etoposide | 20 mg/ml concentrate for solution for infusion – 5 ml, 1 vial | C81.0, C81.1, C81.2, C81.3, C81.9, C82.0, C82.1, C82.2, C82.7, C82.9, C83.0, C83.1, C83.2, C83.3, C83.4, C83.5, C83.6, C83.7, C83.8, C84.0, C84.1, C83.4, C84.3, C84.4, C84.5, C85.1, C85.7, C85.9, C88.0, C88.9, C92.0; C62, C34, C81, C85, C92.0, C58, C56; | |
| 37 | B05BA02 | Fat emulsions (fish oil triglycerides) injectable emulsion | Emulsion for infusion - 50 ml; 100 ml | K56.6, K65.0, K43.0, K80.4, T79.4, N20 | |
| 38 | N03AX26 | Fenfluramine | 2.2 mg/ml Oral solution - 60 ml; 120 ml; 250 ml; 360 ml | G40.4, G40.6 | |
| 39 | N01AH01 N02AB03 | Fentanyl | 50 mcg/ml solution for injection -2 ml x10; 50 mcg/ml solution for injection - 10 ml x 10 | Съгласно РУ | |
| 40 | A07AA12 | Fidaxomicin | 200 mg film-coated tablets x 20 | A04.7 | |

| | | | | | |
|----|---------|------------------------------------|--|---|--|
| 41 | N03AX27 | Ganaxolone | 50mg/ml oral suspension – 110 ml (pack size: 1 bottle + 2 dosing syringes of 3 ml, 2 dosing syringes of 12 ml + 1 bottle adaptor) и (pack size: 5 bottle + 5 dosing syringes of 12 ml + 5 bottle adaptors) | G40.4 | |
| 42 | J05AB06 | Ganciclovir | 500 mg powder for concentrate for solution for infusion - 1 vial; 5 vial | B25, B20.2, P35.1, Z94.4 | |
| 43 | A16AX16 | Givosiran | 189 mg/ml, Solution for injection - 1ml | E 80.2 | |
| 44 | A16AX09 | Glycerol phenylbutyrate | 1.1 g/ml oral liquid - 25 ml | E71.0, E71.1, E72.2 | |
| 45 | C02AC02 | Guanfacine | 1 mg prolonged-release tablet; 2 mg prolonged-release tablet; 3 mg prolonged-release tablet; 4 mg prolonged-release tablet; | F90.0; F90.1; F90.8; F90.9 | |
| 46 | J06BA01 | Human normal immunoglobulin (SCIg) | 200 mg/ml solution for subcutaneous injection - 5ml; 10 ml; 20 ml; 50 ml; 200 mg/ml solution for subcutaneous injection in pre-filled syringe - 5 ml, 10 ml, 20 ml | СЪГЛАСНО РУ | |
| 47 | H02AB09 | Hydrocortison | 5 mg modified-release tablets x 50; x 100 20 mg modified-release tablets x 50; x 100 | E23.0 | |
| 48 | H02AB09 | Hydrocortison | 5mg modified-release hard capsules x 50; x 100; 10 mg modified-release hard capsules x 50; x 100 | E23.0, E25.0, E25.8, E27.1, E27.2, E27.3, E27.4, E31.0, E89.3, E25.0 | |
| 49 | C01EB16 | Ibuprofen | 5 mg/ml solution for injection 2 ml x 4 ampoules | Q25.0 | |
| 50 | N06BX13 | Idebenon | 150 mg film-coated tablets x 180 | H47.2 | |

| | | | | | |
|----|---------|---|--|--|----------------------------|
| 51 | J06BA01 | Immunoglobulins, normal human, for extravascular adm | 100 mg/ml solution for infusion for subcutaneous use - 25 ml; 50 ml; 100 ml; 200 ml; 300 ml | Съгласно РУ | purity of at least 98% IgG |
| 52 | J06BA02 | Immunoglobulins, normal human, for intravascular adm | 100 mg/ml solution for infusion 25 ml; 50 ml; 100 ml; 200 ml; 400ml | Съгласно РУ | |
| 53 | J06BA02 | Immunoglobulins, normal human, for intravascular adm. | 50 mg/ml solution for infusion 10 ml, 20 ml, 50 ml, 100 ml, 200 ml, 400 ml, 500 ml | Съгласно РУ | |
| 54 | B06AC05 | Lanadelumab | 150 mg solution for injection in pre-filled syringe x 1 | D84.1 | |
| 55 | L01EX12 | Larotrectinib | 25 mg capsules x 60; 100 mg capsules x 60; 20 mg/ml oral solution 50 ml ; 20 mg/ml oral solution 100 ml | C40-41; C49.0; C64, C70-C72, C76.2 | |
| 56 | L04AX04 | Lenalidomide | 2,5 mg hard capsules ; 7,5 mg hard capsules ; | C90.0, D46.0, C82 | |
| 57 | R07AX30 | Lumacaftor/Ivacaftor | 75 mg/94 mg granules in sachet x 56 | E84.0, E84.1, E84.8 | |
| 58 | A16AX18 | Lumasiran | 94.5 mg/0.5 ml solution for injection | E74.8 | |
| 59 | A05AX04 | Maralixibat chloride | 9.5 mg/mL oral solution | K76.8, Q44.7, Q44.2 | |
| 60 | L01AA03 | Melphalan | 50 mg powder and solvent for concentrate for solution for injection/infusion ; 50 mg powder and solvent for concentrate for solution for infusion | C90, C81, C82, C83, C85, C91, C92, D46, D47, C74, C56, C50, Z94.9, | |
| 61 | L01BB02 | Mercaptopurine | 20 mg/ml oral suspension - 100 ml | C91.0 | |

| | | | | | |
|----|--------------------|--|--|---|--|
| 62 | J01DH52 | Meropenem and vaborbactam | 1 g + 1 g - Powder for concentrate for solution for infusion | N11.0, N11.1, N11.8, K65.0, J15.9, U83.7, N10, N11.9, K65 | |
| 63 | V03AB17 V04CG05 | Methylene blue = methylthioninium chloride | 5 mg/ml solution for injection -10 ml; 2 ml | T 65.3, T65.8,T39.1 , T57.3 | |
| 64 | A16AA07 | Metreleptin | 3 mg powder for solution for injection; 5,8 mg powder for solution for injection; 11,3 mg powder for solution for injection | E88.1 | |
| 65 | N05CD08 | Midazolam | 1 mg/ml solution for injection/infusion-10 ml; 2 ml | съгласно РУ | |
| 66 | L03AX15 | Mifamurtide | 4 mg powder for concentrate for dispersion for infusion | C40.0-C40.9, C41.0-C41.9, и C76.0-C76.5. | |
| 67 | L01DC03 | Mitomycin | 10 mg powder for solution for injection/infusion or intravesical use; 20 mg powder for solution for injection/infusion or intravesical use | C16, C50, C34, C25, C67 | |
| 68 | L04AA06 | Mycophenolic acid/mycophenolate mofetil | Powder for oral suspension 1000 mg/5ml | Z94.0, T86.1, Z94.4, T86.4, Z94.1, T86.2 | |
| 69 | L04AA06 | Mycophenolic acid/mycophenolate mofetil | 500 mg powder for concentrate for solution for infusion - 4 vial | Z94.0, T86.1, Z94.4, T86.4, Z94.1, T86.2 | |
| 70 | A16AX04 | Nitisinone | 4 mg/ml oral suspension – 90 ml | E70.2 | |
| 71 | C01CA03 | Norepinephrine | concentrate for solution for infusion 1 mg/ml -1ml; concentrate for solution for infusion 1 mg/ml -5 ml; concentrate for solution for infusion 1 mg/ml -10 ml; | I50.9, R57.1, R57.8,R57.9; Z94,I95,I05.0,I05.1,I05.2,I06.0,I06.1,I06.2,I07.0,I07.1,I07.2,I20.0, I20.8,I21.0,I21.1,I21.2 ,I21.3,I21.4,I21.9,I23.0,I23.2,I23.3,I23.4,I23.5,I23.6,I25.1,I25.2,I25.3,I25.4,I25.8,I33.0,I34.0,I34.1,I34.2,I35.0, I35.1,I35.2,I35.8,I36.1 ,I36.2,I42.1,I42.2,I51.3,I71.0,Q21.1,Q21.2 | |

| | | | | | |
|----|---------|---|---|--|--|
| 72 | A05AX05 | Odevixibat | 200 micrograms hard capsules 400 micrograms hard capsules 600 micrograms hard capsules 1200 micrograms hard capsules | K76.8, Q44.7, Q44.2 | |
| 73 | N05AH03 | Olanzapine | 10 mg powder for solution for injection | F20; F30 | |
| 74 | A16AB25 | Olipudase alfa | 4 mg powder for concentrate for solution for infusion; 20 mg powder for concentrate for solution for infusion | E75.2 | |
| 75 | M09AX09 | Onasemnogene abeparvovec-2 x 10 ¹³ vg/ml - Solution for infusion | 2 x 10 ¹³ vg/ml - Solution for infusion 5.5 ml + 8.3 ml vial | G12.0, G12.1 | |
| 76 | L01DB01 | Pegylated liposomal Doxorubicin | 2 mg/ml concentrate for solution for infusion | C90.0; C50, C56, C46 | |
| 77 | N07XX11 | Pitolisant | 4.5 mg film-coated tablets | G47.4 | |
| 78 | L04AX06 | Pomalidomide | 1 mg hard capsules; 2 mg hard capsules; 3 mg hard capsules; | C90.0 | |
| 79 | J02AC04 | Posaconazole | 100 mg gastro-resistant tablets; 40 mg/ml oral suspension -105 ml bottle; 300 mg concentrate for solution for infusion-16.7 ml | СЪГЛАСНО РУ | |
| 80 | J05AX08 | Raltegravir | 25 mg chewable tablets ; 100 mg chewable tablets; 100 mg granules for oral suspension x 60 sachets | B20; B21; B22; B23; B24 | |
| 81 | V03AF07 | Rasburicase | 1.5 mg/ml -1 ml Powder and solvent for concentrate for solution for infusion; 7,5 mg/5ml Powder and solvent for concentrate for solution for infusion | C91.0, C91.1, C92.0 ; C83.0, C83.3, C83.9, C83.7 | |
| 82 | L04AA43 | Ravulizumab | 300 mg/3 ml concentrate for solution for infusion (100 mg/ml) 300 mg/3 ml concentrate for solution for infusion (10 mg/ml); 1100mg/1 mL concentrate for solution for infusion | D59.3, D59.5 | |
| 83 | B06BD06 | Regdanvimab | 60 mg/ml concentrate for solution for infusion - 16 ml | U07.1 | |

| | | | | | |
|----|---------|--------------------|---|---|--|
| 84 | J05AB16 | Remdesivir | 100 mg - Powder for concentrate for solution for infusion | U07.1 | |
| 85 | L01EX19 | Ripretinib | 50 mg tablets x 90; x 30 | C49.4 | |
| 86 | N05AX08 | Risperidone | 75 mg - Powder and solvent for prolonged-release suspension for injection | F20 | |
| 87 | B01AF01 | Rivaroxaban | 1 mg/ml granules for oral suspension - 2,625 g;5,25g | I80.1, I80.2, I82.8, I26, I48, Z95.2 | |
| 88 | M03AC09 | Rocuronium bromide | 10mg/ml solution for injection/infusion - 5ml; 10 mg/ml Solution for injection - 10 ml | СЪГЛАСНО РУ | |
| 89 | A16AB14 | Sebelipase alfa | 2 mg/ml concentrate for solution for infusion - 10 ml | E75.5 | |
| 90 | L04AC10 | Secukinumab | 75 mg solution for injection in pre-filled syringe x 1; x 3 | L40.0 | |
| 91 | L01EE04 | Selumetinib | 10 mg hard capsules; 25 mg hard capsules | C76.0, C76.1, C76.2, C76.3, C76.4, C76.5; Q85.0 | |
| 92 | L04AC11 | Siltuximab | 100 mg powder for concentrante for solution for infusion; 400 mg powder for concentrante for solution for infusion | C85.7 | |
| 93 | N07XX04 | Sodium oxybate | 500 mg/ml oral solution 180 ml | G47.4;G47.2 | |
| 94 | H01CB01 | Somatostatin | 3 mg powder for solution for injection or infusion | K 25.0, K 26.0, K 28.0, K 29.0, K 91.8, K 91.9 | МКБ К 91 покрива уврежданя на храносмилателните органи след медицински процедури, неклассифицирани и другаде |

| | | | | | |
|-----|---------|---|--|---|--|
| 95 | N03AX17 | Stiripentol | 250 mg hard capsules; 250 mg powder for oral suspension in sachet | G40.4, G40. | |
| 96 | V03AB35 | Sugammadex | solution for injection 100 mg/ml - 5ml; | СЪГЛАСНО РУ | |
| 97 | L04AD02 | Tacrolimus | 5 mg/ml concentrate for solution for infusion - 1ml x 10 | Z94.0, T86.1, Z94.4, T86.4, Z94.1, T86.2 | |
| 98 | N07XX08 | Tafamidis | soft capsules 61 mg | E85.1, I43.8, E85.2, E85.4, E85.8 | |
| 99 | V09HA03 | Technetium (99mTc) antigranulocyte antibody | 1 mg - Kit for radiopharmaceutical preparation | M86, M86.1, M86.2, M86.3, M86.4, M86.5, M86.6, M86.8, M86.9 | |
| 100 | V09GA01 | Technetium -99mTc Sestamibi | 1 mg - Kit for radiopharmaceutical preparation | I20, D35.1, C75.0, C50 | |
| 101 | A16AX08 | Teduglutide | powder and solvent for solution for injection 1,25 mg, powder and solvent for solution for injection 5 mg | K91.2 | |
| 102 | L01EX21 | Tepotinib | 225 mg film-coated tablets | C34 | |
| 103 | L04AX02 | Thalidomide | 50 mg hard capsules x 28; 100 mg coated tablet x 30 | C90.0 | |
| 104 | L01AC01 | Thiotepa | 15 mg powder for concentrate for solution for infusion; 100 mg powder for concentrate for solution for infusion | СЪГЛАСНО РУ | |
| 105 | L01CX01 | Trabectedin | 0,25 mg powder for concentrate for solution for infusion; 1 mg powder for concentrate for solution for infusion | C49.9, C56 | |
| 106 | L01AB02 | Treosulfan | 5 g powder for solution for infusion x 1; x 5 | C90, C81, C82, C83, C85, C91, C92, D46, D47 | |

| | | | | | |
|-----|---------|------------------------|--|--------------|---|
| 107 | S01FA06 | Tropicamide | 5 mg/ml (0,5 %) eye drops solution x 10 ml | H00 - H59 | |
| 108 | N03AG04 | Vigabatrin | 500 mg soluble tablets | G40.4, G40.6 | |
| 109 | A16AX05 | Zinc acetate dihydrate | 50 mg hard capsules | E83.0 | Чернодробна цироза в резултат на болестта на Wilson |
| 110 | M05BA08 | Zoledronic acid | 4mg/5ml concentrate for sol.for infusion | Съгласно РУ | |